United States Patent 7,981,909 Scope and Claims Analysis: Ciclopirox Shampoo Methods for Treating Seborrheic Dermatitis (Scalp)

Executive summary US 7,981,909 claims method-of-treatment uses for seborrheic dermatitis of the scalp (and more generally seborrheic dermatitis) using a single, one-active-ingredient ciclopirox shampoo formulated at pH ~4.5 to 6.5 and containing at least one surfactant selected from specified classes (anionic, cationic, nonionic, amphoteric). The enforceable claim core is a tight formulation plus route-and-therapy package: (i) ciclopirox as the only active, (ii) shampoo as a single composition, (iii) pH band, and (iv) surfactant-class inclusion; dependent claims broaden by adding an additional surfactant meeting the same class selections.

What patents protect US 7,981,909 ciclopirox seborrheic dermatitis shampoo claims?

Answer (claim-protection scope in one line): US 7,981,909 protects method-of-use treatment of seborrheic dermatitis with a specific ciclopirox-only shampoo formulation defined by pH and surfactant-class limitations.

How the claim language narrows infringement risk

The claims are written as method-of-treating claims, but they are defined by a specific dosage form and formulation. That structure typically means infringement hinges on whether the accused product is a ciclopirox-only shampoo with the required pH and surf ac tant class(es).

Key claim anchors:

Disease target
- Claim 1: “seborrheic dermatitis of the scalp”
- Claims 2-4: “seborrheic dermatitis” (no scalp limitation expressed in the excerpt you provided for claims 3-4)
Administration
- “administering to the scalp” (claim 1)
- “administering to a human seborrheic dermatitis patient” (claims 3-4)
Composition structure
- “a composition comprising only one active ingredient”
- “active ingredient consisting of ciclopirox” (i.e., no additional actives)
- “single composition”
- “wherein the composition is a shampoo”
pH limitation
- “pH ranging from about 4.5 to about 6.5”
Surfactant-class limitation
- “at least one surfactant chosen from” anionic, cationic, nonionic, amphoteric
- Dependent claims add “at least one additional surfactant” chosen from those classes

Independent vs. dependent claims: what is actually added

From the claim set you provided:

Claim 1 (independent): scalp seborrheic dermatitis; ciclopirox-only shampoo; pH 4.5-6.5; at least one surfactant from the specified classes.
Claim 2 (dependent): adds “at least one additional surfactant” from those classes.
Claim 3 (independent, broader drafting): removes explicit scalp-only language in the method preamble (in your excerpt it is still described as administering to the patient, not restricting to scalp); still requires ciclopirox-only shampoo; pH 4.5-6.5; single composition shampoo; same surfactant-class selection.
Claim 4 (dependent): adds at least one additional surfactant.

This pattern suggests that the core independent claim is formulation-defined, while dependent claims address surfactant count/composition breadth, not a different active or different pH.

What is the scope of claim 1 and what would infringe a ciclopirox shampoo?

Answer (claim 1 scope): Infringement requires using a ciclopirox-only shampoo (single composition) administered to a scalp seborrheic dermatitis patient, where the shampoo has pH 4.5-6.5 and includes at least one surfactant from the listed surfactant classes.

Claim 1 element-by-element checklist (practical infringement map)

Element A: Method preamble

Must be “method of treating seborrheic dermatitis of the scalp”

Element B: Administration context

“administering to the scalp of a human seborrheic dermatitis patient”

Element C: Composition active set

“composition comprising only one active ingredient”
“active ingredient consisting of ciclopirox”
- This bars any other active drugs (within the meaning used in the patent and regulatory classification of “active” components) in the same composition.

Element D: Surfactant inclusion

At least one surfactant must be selected from:
- anionic surfactants
- cationic surfactants
- nonionic surfactants
- amphoteric surfactants

Element E: pH band

shampoo pH is within “about 4.5 to about 6.5”

Element F: Dosage form constraint

“single composition”
“is a shampoo”

How “only one active ingredient” is likely to be interpreted

The claims state “active ingredient consisting of ciclopirox.” That is a restrictive formulation boundary. If an accused product includes:

another therapeutic antifungal,
another antimicrobial,
keratolytics,
corticosteroids,
or other drug actives that would be considered “active ingredients,”

then it risks failing the “only one active ingredient” limitation.

Inactive additives (preservatives, chelators, fragrance, viscosity modifiers, acids/bases used as excipients) can still be present unless they are treated as additional active ingredients.

Do claims 2 and 4 broaden protection beyond claim 1 by adding more surfactants?

Answer: Claims 2 and 4 expand the surfactant requirement by requiring at least one additional surfactant, but they do not relax the ciclopirox-only and pH 4.5-6.5 limits.

Claim 2 incremental scope

Claim 2 depends on claim 1 and requires the composition “further comprises at least one additional surfactant chosen from” the same four surfactant categories. That means:

If an accused shampoo has only one surfactant meeting the claim’s category, it could avoid claim 2 even if it satisfies claim 1.
If the accused shampoo uses two or more surfactants meeting those categories, it is more likely to meet claim 2.

Claim 4 incremental scope

Claim 4 depends on claim 3 and adds the same “at least one additional surfactant” limitation.

Net effect: dependent claims create additional claim targets around surfactant multiplicity while leaving the “ciclopirox-only” and pH band intact.

What does claim 3 change compared to claim 1 (scalp limitation, method preamble, and administration phrasing)?

Answer: Claim 3 keeps the same formulation constraints (ciclopirox-only shampoo, pH 4.5-6.5, surfactant-class inclusion) but uses broader method wording that is less explicitly tied to “scalp” in the excerpted preamble.

Practical differences to watch

Based on your excerpt:

Claim 1 explicitly targets “seborrheic dermatitis of the scalp” and “administering to the scalp.”
Claim 3 targets “seborrheic dermatitis” and “administering to a human seborrheic dermatitis patient.”

Even if the formulation is still described as a shampoo, the method claim language can matter for infringement arguments. The accused use could be framed as off-scalp or non-scalp application (where applicable to the product label or typical use).

Why the shampoo limitation keeps things anchored

All versions in your excerpt still require “the composition is a shampoo.” That tends to align the therapeutic use with topical scalp hair/skin application, though it does not strictly force “scalp” for claims 3-4 under the excerpted language.

How does pH 4.5 to 6.5 and “about” affect enforcement and design-around?

Answer: The pH limitation is one of the strongest formulation barriers because it is numerically bounded; “about” creates tolerance but still gives a quantifiable target for infringement and testing.

Enforcement implications

Plaintiffs typically rely on product specifications and analytical testing of the final marketed shampoo lot.
“About 4.5 to about 6.5” implies a range that may tolerate small deviations, but the numeric center remains anchored.

Design-around levers

A competitor trying to avoid infringement could:

move formulation pH outside the band (or outside the “about” tolerance argued by the patentee),
or keep pH within the band but introduce a second active ingredient (breaking “active ingredient consisting of ciclopirox”).

The strongest design-around depends on whether “active ingredient” is interpreted strictly (likely) and whether pH can be reliably kept out of the asserted band while maintaining product performance.

What formulations are protected: single active ciclopirox shampoo with surfactants in specific categories

Answer: The protected formulation concept is constrained to a one-active ciclopirox shampoo at pH 4.5-6.5 with at least one surfactant selected from enumerated classes.

Surfactant category breadth can be a weak point for defendants

Because the claim lists four broad surfactant categories, an accused product is unlikely to avoid the surfactant limitation by “choosing a different surfactant category,” unless it uses surfactant systems that do not fit those categories as claimed (rare in typical shampoos).

Instead, the main formulation defenses often become:

pH band avoidance,
or “only ciclopirox active” avoidance (adding a different active breaks the claim).

How strong is the patent estate around US 7,981,909 for ciclopirox seborrheic dermatitis shampoo?

Answer: US 7,981,909’s enforceability strength is driven by how uniquely the combination of (1) ciclopirox-only, (2) shampoo, and (3) pH 4.5-6.5, (4) surfactant class is applied matches market products.

Claim strength drivers

Numeric pH band creates an objective test point.
“Active ingredient consisting of ciclopirox” is restrictive and can exclude combination-therapy products.
Shampoo as a “single composition” is a dosage form constraint.

Claim strength vulnerabilities (from a defense perspective)

If the marketed product is demonstrably within the pH band and uses ciclopirox as only active, and includes surfactants from the listed categories, the remaining disputes reduce to narrower factual issues (use, label, and composition testing).
The dependent surfactant-count limitations (claims 2 and 4) can be easier for defendants to navigate if they use only one surfactant category meeting the claim.

What is the likely regulatory and Orange Book status for US 7,981,909?

Answer: The excerpt you provided does not include Orange Book identifiers or linkage to an FDA-listed drug product, and no claim-specific regulatory pathway details are provided in the record text here. Without the underlying publication record, a definitive Orange Book mapping cannot be produced from the information provided.

What patent litigation risk does US 7,981,909 pose for generic or branded ciclopirox shampoos?

Answer: The risk is principally for products that attempt to market ciclopirox seborrheic dermatitis shampoos that fall within the claimed formulation boundaries, especially pH 4.5-6.5 and ciclopirox as the only active.

Litigation trigger scenario

An accused manufacturer markets a ciclopirox shampoo for seborrheic dermatitis and performs product testing showing pH in band and surfactant categories covered.
If the accused product also has only ciclopirox as active ingredient, the “composition-only” element becomes difficult to contest.

Settlement and licensing posture

In matters like this, settlements typically focus on formulation changes (pH shifting or active combination) or carve-outs tied to specific strengths and dosage forms. The dependent claims suggest that if formulation cannot be shifted out of the pH band, parties may attempt to structure surfactant systems to target claim 2/4 non-infringement while leaving claim 1/3 still at issue.

How do you compare the patent scope to alternative seborrheic dermatitis actives (design-around and cross-coverage)?

Answer: Claims are narrowly tied to ciclopirox as the only active. Products using other actives are outside the literal “active ingredient consisting of ciclopirox” limitation, and combination products are outside if they include any additional active ingredients.

Side-by-side concept map

Product concept	Likely coverage under US 7,981,909
Ciclopirox-only shampoo; pH 4.5-6.5; listed surfactant categories	High literal risk
Ciclopirox-only shampoo; pH outside 4.5-6.5	Avoids pH-limited claim elements
Ciclopirox + another drug active in same shampoo	Avoids “active ingredient consisting of ciclopirox”
Non-shampoo topical dosage form (not a shampoo)	Avoids dosage-form limitation
Treatment method outside scalp use (for claim 1)	Could avoid claim 1 preamble; still assess claim 3/4 wording

Key Takeaways

US 7,981,909 protects a method-of-treatment for seborrheic dermatitis using a ciclopirox-only shampoo.
The enforceable formulation perimeter is pH ~4.5 to ~6.5 plus at least one surfactant from anionic/cationic/nonionic/amphoteric categories.
Claims 2 and 4 add a surfactant multiplicity limitation (“at least one additional surfactant”) but do not relax the ciclopirox-only and pH limits.
Claim 3’s method language is broader in phrasing than claim 1 in your excerpt, while all claims remain tied to a shampoo composition and ciclopirox as the sole active.

FAQs

1) Does US 7,981,909 cover ciclopirox foam or lotion instead of shampoo?
No literal coverage is provided in the excerpt because all claims require “wherein the composition is a shampoo” as a limitation.

2) Can a product include preservatives and still satisfy “active ingredient consisting of ciclopirox”?
Yes, preservatives are typically excipients. The limiting phrase is about “active ingredient(s),” not excipient ingredients, as reflected in the claim wording you provided.

3) Is the surfactant requirement met if the shampoo uses only one surfactant from the listed categories?
It can satisfy the independent claims (claims 1 and 3), because they require at least one surfactant. Claims 2 and 4 require at least one additional surfactant.

4) What is the strongest design-around lever: pH or adding another active?
Both are strong conceptually: moving pH outside ~4.5-~6.5 avoids the pH-limited element; adding another drug active avoids “active ingredient consisting of ciclopirox.”

5) If the product is ciclopirox-only but pH is within range, does avoiding “scalp” use eliminate infringement?
For claim 1, the preamble includes “seborrheic dermatitis of the scalp” and administration to the scalp. Claim 3-4 in your excerpt are broader in method phrasing, so avoiding “scalp” may not eliminate risk.

References

United States Patent No. 7,981,909. (Claim text provided in the prompt).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	196 39 818	Sep 27, 1996

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	008860	⤷ Start Trial
Austria	209891	⤷ Start Trial
Australia	4774697	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,981,909

Summary for Patent: 7,981,909